Data Package for study.

The primary objective of this study is to characterise the pharmacokinetics (PK) of BIIB017 (Peginterferon Beta-1a) administered as a single 125 μg subcutaneous (SC) dose in Japanese and Caucasian adult healthy participants. The secondary Objective is to assess the safety and tolerability of a single 125 μg subcutaneous (SC) dose of BIIB017 in Japanese and Caucasian adult healthy participants.

本研究的主要目的是表征单次皮下注射（subcutaneous，SC）125μg BIIB017（聚乙二醇干扰素β-1a，Peginterferon Beta-1a）在日本裔与高加索裔健康成年受试者体内的药代动力学（pharmacokinetics，PK）特征。本研究的次要目的为评估单次皮下注射125μg BIIB017在日本裔与高加索裔健康成年受试者中的安全性与耐受性。